reason report
swing fenc kra initi op pt
bottom line initi coverag mirati therapeut
op rate pt view largest
potenti valu driver earli stage oral administ
drug develop treat number
cancer harbor specif biomark kra mutat
see drug signific potenti one
specul compani coverag univers
yet gener clinic data human
clinic data class agent prior attempt
decad drug pathway unsuccess still
see risk/reward favor first clinic dataset
expect base part medacorp specialist insight
pt repres upsid favor data
and/or similar compound could de-risk
asset result upsid best-cas scenario
kra repres npv
base assess opportun
harbor tumor repres signific major
share valu eclips anoth later stage compound sitravatinib
immuno-oncolog drug pivot data expect see
favor outlook main reason buy
specul name coverag univers
believ drug class show sign clinic
activ clinic data
coval class kra drug extens dilig leverag
medacorp network kol suggest
similar compound like show enough activ earli data
warrant develop monotherapi well
combin target agent
block kra directli target protein translat
clinic activ prior attempt block kra
disappoint newer compound appear trap kra receptor
inact state perman coval bind protein
prevent gtp gain access complex step necessari
kra activ prior effort drug pathway indirect
thought kra protein amen direct blockad
still possibl kra blockad may translat cell
death clinic given potenti resist pathway redund
medacorp specialist see preclin data compel think
agent enough clinic activ warrant
develop specialist believ compel durabl
data eventu deriv combin strategi could
includ use agent egfr inhibitor braf/mek inhibit
agent drug
share outstand mil
year price history/av daili volume mil
compani inform svb leerink llc research
revenu dilut ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
high risk high reward highli specul
opportun signific success literatur
suggest mutat seen non-smal cell lung
cancer nsclc tumor colorect cancer tumor
pancreat cancer tumor often aggress
less respons convent therapi creat signific unmet
medic need like allow expedit regulatori pathway
current model world-wide revenu class
nsclc colorect cancer pancreat
cancer mirati split major market
compound captur lesser share littl known
mp compound believ may
favor pharmacokinet profil especi regard food
interact given potenti combin strategi
see signific potenti strateg option class
data year-end could de-risk result
fundament valu appreci view pt --
base net present valu npv assess clinic
regulatori commerci risk mirati asset -- merit
outperform rate view compel scenario --
agent demonstr compel proof concept -- could result
signific upsid valuat insid detail assess
catalyst path de-risk stori
could wrong scientif rational block
kra pathway compel opinion
view number medacorp key opinion leader kol mani
factor could lead less efficaci expect includ resist
mechan redund pathway unfavor pharmacodynamics/
pharmacokinet human similarli unexpect safeti issu could
emerg make therapeut window viabl even
blockad translat tumor regress therefor mani
develop stage biotech compani drug fail risk
outperform rate signific potenti downsid
lead compound sitravatinib core invest thesi
mirati lead compound oral multi-kinas inhibitor test
combin agent number tumor drug
demonstr clinic activ patient fail agent mirati
collabor beigen bgne op multipl set
expect data pivot nsclc trial could lead
commerci via expedit pathway drug repres
npv
batter
initi coverag outperform rate price
target view largest compon current futur valu oral compound
target kra mutat seen clinic data
compound yet medacorp kol believ compel preclin data like translat
enough clinic activ warrant develop monotherapi combin
target agent highli specul invest thesi potenti reward
signific given preval mutat number cancer signific unmet
medic need see potenti upsid share year-end initi clinic
data compel partial de-risk
directli target kra protein unlik prior attempt small
molecul directli target kra bind coval mutat cystein trap
kra perman inact state block kra pathway driver
oncogenesi number tumor type includ lung colorect pancreat prior
attempt drug pathway fail yield clinic activ util indirect
method kra protein thought undrugg medacorp kol believ
mechan preclin data date highli encourag
look earli sign clinic activ warrant develop
monotherapi well combin agent initi tranch data
basket trial enrich mutat top-lin data anticip year-end
lung cancer patient tumor type follow given signific unmet medic
need think respons rate would compel difficult-to-treat
patient although compani medacorp specialist spoken believ
breadth activ could higher given preclin activ note multipl cell line term
durabl respons specialist hope initi data monotherapi
regimen could yield least month respond number could improv
combin strategi could block kra cascad multipl locat
may best-in-class drug mirati compound
develop util piperazin quinazolinon scaffold one translat chemist
spoke felt promis structur block kra littl known
either compound believ compound may less favor
pharmacokinet profil may suscept food effect base input
medacorp kol list clinic trial design third compound develop
janssen publicli disclos preclin data may seen
develop paus accord medacorp specialist
data could valid strategi view favor preclin
clinic data compound could serv class-valid boost
share see minim downsid data disappoint could
relat specif attribut favor activ would like seen class-
valid especi sinc mirati compound thought superior profil one scenario
could advers impact would failur compound relat lack
efficaci despit good pk/pd data see scenario highli unlik given qualit
comment made date regard initi clinic activ
favor catalyst pathway boost share price target pt
suggest upsid current level believ catalyst pathway
subsequ de-risk could significantli boost valuat much current
level initi dataset could begin process class valid
follow data year-end also expect data sitravatinib bladder cancer
could add valu compound ahead pivot data nsclc year-
end valu path de-risk section report detail
sitravatinib promis part core thesi current sitravatinib repres
risk-adjust npv valuat small molecul multi-tyrosin kinas inhibitor
shown impact multipl cell immun system thought becom exhaust
patient becom resist inhibitor phase data combin
agent shown activ exce expect alon view
program import driver invest thesi pivot data on-going trial
combin versu chemotherapi lung cancer could form basi
acceler approv data expect year-end compani also
collabor beigen could expand sitravatinib combin bgne agent
tislelizumab tumor type earlier line therapi
pt includ sitravatinib revenu ex-u sitravatinib royalti use
checkpoint inhibitor cpi relapsed/refractori non-smal cell lung cancer nsclc bladder
cancer pt also includ us ex-u revenu revenu kra
mutat cancer includ nsclc colorect cancer pancreat cancer endometri
cancer includ risk-adjust npv per share mirati earli pipelin
includ compani program target toward cancer
productpeak revenu mn phase developmentnpv mn probabl successrisk-adjust npv mn expect launchnet current valu share us sitravatinib cpi refractori sitravatinib cpi refractori sitravatinib tumor sitravatinib royalti nsclc bladder kra kra kra kra kra pipelin kra asset dilut share count risk-adjust equiti valu risk sitravatinib cpi refractori nsclcu sitravatinib cpi refractori bladderu sitravatinib tumor typesex-u sitravatinib royalti nsclc bladder us/eu kra nsclcus/eu kra us/eu kra pancreaticus/eu kra endometrialus/eu kra retreatmentearli pipelin kra mirati inc
sitravatinib forecast driven checkpoint inhibitor r/r nsclc
sitravatinib checkpoint inhibitor relapsed/refractori nsclc mirati conduct
random phase trial sitravatinib combin checkpoint inhibitor opdivo
approxim second-lin advanc non-squam nsclc patient document
tumor progress follow treatment checkpoint inhibitor plu chemotherapi frontlin
activ compar docetaxel trial design allow interim analysi use
object respons rate orr could potenti support acceler approv studi
expect start interim data possibl primari endpoint
studi overal surviv os could use support full approv primari endpoint
analysi anticip occur
model sitravatinib introduct checkpoint inhibitor cpi relapsed/refractori
popul start assum nda submiss acceler approv
estim current nsclc patient would elig sitravatinib
cpi combin therapi grow patient base increas uptak
base therapi frontlin set model durat therapi patient
month initi net price per month annual net price increas
model peak revenu nsclc base evalu current
avail clinic pre-clin data assign probabl success result
per share risk-adjust npv mirati
sitravatinib checkpoint inhibitor relapsed/refractori urotheli carcinoma mirati also
explor develop sitravatinib combin checkpoint inhibitor cpi
popul bladder cancer patient also fail cpi therapi compani current
conduct phase trial proof-of-concept data anticip shortli
model introduct sitravatinib combin checkpoint inhibitor cpi-
experienc bladder cancer estim approxim patient
relapsed/refractori set could address sitravatinib grow patient
model low double-digit penetr address opportun
maintain consist price rel nsclc result peak revenu
assign probabl success sitravatinib/checkpoint combin use bladder
cancer result per share risk-adjust npv mirati
royalti ex-u sitravatinib sale sitravatinib revenu outsid model
percentag sale rang assum royalti rang high singl
digit low doubl digit result peak royalti mirati assign
probabl success result per share risk-adjust npv
ww revenu forecast kra indic
kra cancer mirati develop treatment
tumor exhibit kra mutat mutat promin number differ
malign includ lung cancer colorect cancer pancreat cancer endometri
cancer model opportun individu
lung cancer estim approxim patient kra
mutat initi testing/diagnosi rate improv meaning follow approv
agent specif treat mutat peak
model multipl line therapi frontlin second-lin vari durat therapi
base monotherapi combin approach base assess avail pre-
clinic data well convers sever medacorp kol model less durat
therapi single-ag month relapsed/refractori month frontlin
ultim believ market like evolv combin therapi approach
model meaning longer durat combin month relapsed/refractori
model introduct monotherapi net price per
month price increas annual model introduct approxim six
month launch similar compound target kra mutant
malign peak see split market equal
kra patient use altern treatment aggreg see ww
market kra inhibitor nsclc peak ww revenu
assign probabl success result risk-adjust npv
colorect cancer estim approxim patient kra
mutat assum initi testing/diagnosi rate increas meaning follow
approv agent treat mutat eventu peak model similar
launch time market share dynam consist price rel nsclc model
suggest ww opportun kra inhibitor captur
net revenu peak assign probabl success result per
share risk-adjust npv
also model opportun pancreat cancer estim approxim
patient kra mutat assum initi testing/diagnosi rate
increas meaning follow approv agent treat mutat eventu
peak model launch time market share dynam price similar nsclc
model suggest ww opportun kra inhibitor pancreat
cancer captur global revenu peak assign
probabl success result per share risk-adjust npv
endometri cancer estim approxim patient kra mutat
similar diagnosi rate pancreat cancer rise peak similar
assumpt around market introduct time market share price tumor
type estim opportun global captur market
see revenu peak assign probabl success result per
share risk-adjust npv
importantli note intellectu properti franchis like extend
potenti depend patent issuanc extens account
residu valu use multipl cash flow cash flow
mirati develop collabor array biopharma arri op base
term collabor sign mirati respons clinic develop
commerci owe tier royalti well remain develop
commerci mileston could total across
program model high singl digit royalti due arri
ww revenu forecast kra tumor vs
earli pipelin kra inhibitor program mirati also preclin program
develop collabor array target tumor kra mutat mutat
also present number tumor type includ pancreat cancer colorect cancer
endometri cancer lung cancer tumor type highest frequenc
mutat pancreat cancer found case similar
target treatment option patient kra tumor mirati expect identifi
lead candid program
assign valu model base approxim market size
patient assign net present valu prior risk adjust significantli risk-
adjust opportun assign probabl success result risk-adjust
npv approxim per share valuat
risk-adjust npv program
valuat methodolog use risk-adjust sum-of-the-part methodolog valu mirati
therapeut examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens use wacc termin valu
nopat indic depend length patent protect
account valu beyond
risk valuat
 clinic risk mirati multipl drug candid clinic develop includ sitravatinib
trial produc clinic data disappoint rel investor
expect repres risk valuat
 regulatori risk regulatori approv requir commerci prescript drug issu
regul result longer-than-anticip timelin failur gain approv
mirati drug would repres risk valuat
 competit drug compet mirati pipelin candid could produc
superl clinic data lead increas competit market less-than-anticip
uptak mrtx product repres risk current valuat
valu path de-risk
current pt reflect assess commerci clinic regulatori risk
mirati asset base avail pre-clin data clinic data on-going develop
program howev also expect signific data newsflow next month
meaning impact assess believ investor would buy
level would share view approach multipl value-inflect point
better understand newsflow data readout next month could impact
pt conduct sensit analysi believ illustr potenti value-inflect
data point specif next see four signific value-defin event
data march detail later report
seen substanti pre-clin data mirati seen less data amgen
similar present data american associ cancer
research annual meet march oral session highlight new
drug horizon abstract meet expect post februari
abstract avail present entitl
discoveri novel coval inhibitor phase clinic trial
patient solid tumor harbor allel expect featur primarili pre-
clinic data base compani comment recent earn
call believ like exhibit earli sign clinic activ expect
initi clinic data believ possibl data present provid addit
valid target kra mutat treatment cancer believ
investor like scrutin data close rel preclin data
avail believ mirati compound featur may provid
pharmacokinet pk advantag see present signific
de-risk event believ investor may view present potenti increment
valid approach
initi clinic data base manag comment anticip
present initi clinic human data venu uncertain
believ compani like target high-profil oncolog meet june
esmo sept /oct base manag comment see initi sign
clinic activ believ data like favor receiv investor
interest see initi sign clinic respons tumor shrinkag object
respons earli dose escal data set see sign valid clinic
approach would anticip share react favor importantli believ investor
recogn like sever month ahead clinic develop program rel
mirati investor unlik view data competit hindranc rather
class/mechan valid believ data could key de-risk event
would consid increas probabl success meaning earli data
appear compel convers data appear compel believ etiolog
issu close scrutin focu whether issu relat target/class
specif pharmacokinetic/pharmacodynam pk/pd profil
best-cas scenario data would includ evid target engag inhibit
lead clinic sign efficaci tumor regress and/or respons worst-cas
scenario data would includ evid signific target engag inhibit
without clinic sign efficaci tumor regress
initi clinic data mirati guid present initi clinic data
venu still determin believ compani
seek high-profil medic meet esmo sept /oct see present
data signific catalyst share next month
first clinic data compound potenti provid insight clinic activ
safety/toler potenti therapeut window
sitravatinib proof-of-concept data cpi-experienc bladder cancer sitravatinib
enter phase random trial evalu drug combin opdivo
treatment checkpoint inhibitor relapsed/refractori r/r nsclc compani explor
use addit tumor type proof-of-concept data sitravatinib combin opdivo
expect checkpoint-refractori bladder cancer singl arm studi patient
evalu efficaci safeti includ number patient experienc tumor size reduct
number patient experienc advers event blood plasma concentr
sitravatinib data trial could provid proof-of-concept sitravatinib addit
sizabl tumor type best-cas scenario data would provid strong rational
sitravatinib cpi-experienc patient increas confid phase program
nsclc increas probabl success on-going sitravatinib program
use risk-adjust sum-of-the-part methodolog perform valuat sensit
analysi consid potenti outcom event specif delin
potenti scenario cours next month describ
path de-risk scenario
svb leerink bull bear base case illustr
bull scenario -- posit proof-of-concept data sitravatinib cpi refractori
bladder cancer would improv confid indic well confid
broader sitravatinib develop program scenario increas probabl
success sitravatinib bladder cancer nsclc tumor type ex-u royalti
scenario includ posit pre-clin initi clinic data well
strong initi proof-of-concept data mirati expect de-risk kra
franchis probabl success increas result potenti bull
case fundament valu per share notabl scenario could magnifi beyond
fundament valu investor percept strateg option increas class becom
tangibl
posit initi clinic data scenario see strong initi proof-of-
concept data meaning de-risk kra opportun
increas confid program increas probabl success
tumor type maintain sitravatinib
base case assumpt fundament valu scenario increas per
posit clinic data scenario see initi proof-of-concept data
clinic efficaci tumor regression/responses/dur provid valid
class de-risk maintain sitravatinib
probabl success increas probabl success
result fundament valu increas per share
posit pre-clin data posit pre-clin data expect
present oral session march provid addit
confid mechan approach treat tumor
believ could provid modest de-risk though
magnitud expect present first-in-human data scenario
maintain base case assumpt sitravatinib increas probabl
success result fundament valu increas
per share
sitravatinib posit bladder data mirati expect present proof-of-concept data
sitravatinib plu opdivo bladder cancer believ posit data
set could increas investor confid bladder cancer well pivot
phase nsclc data expect potenti expand addit
tumor type scenario maintain base case assumpt
increas probabl success sitravatinib bladder
nsclc tumor ex-u royalti
result fundament valu increas per share
bear scenario -- near worst-cas scenario includ neg data kra
program well disappoint sitravatinib result bladder cancer scenario
remov valu model lower probabl success
program also lower probabl success sitravatinib nsclc
tumor type ex-u royalti result bear case scenario valu per share
sitravatinib neg bladder cancer convers neg data sitravatinib
bladder cancer could result less confid broader sitravatinib develop
program scenario maintain base case assumpt remov
bladder cancer model lower probabl success sitravatinib
nsclc tumor type result fundament valu decreas per
neg clinical/pre-clin data class read-through
see like envis scenario neg data
broader read-through class kra inhibitor compound specif
could see emerg show reach therapeut level target
engag without see clinic sign efficaci tumor regress respons
impli inhibit kra may suffici arrest tumor growth
scenario maintain base case assumpt sitravatinib lower
probabl success tumor type would
result fundament valu decreas per share
program fail sitravatinib bladder cancer data
posit case remov valu program increas
probabl success sitravatinib nsclc modestli bladder cancer
tumor type net result fundament valu decreas
per share
kra failur without sitravatinib success bladder cancer scenario includ
failur kra program chang base case sitravatinib
assumpt remov program maintain sitravatinib
probabl net result fundament valu decreas per share
program catalyst
kra cancer
small molecul design inhibit kra mutant form signal
transduct protein display elev activ mirati develop tumor
harbor mutat promin non-smal cell lung cancer nsclc colorect cancer
ra mediat cell signal ra rat sarcoma famili group gtpase
play key role intracellular signal transduct act conduit extracellular signal
typic receptor tyrosin kinas rtk varieti intracellular signal pathway
promin member human ra famili three gene kra hra nra
encod four gtpase enzym hra nra three
classic ra gene well studi appear greatest clinic
signific broader famili also includ hundr g-protein vari degre
sequenc homolog found member class rajalingam et al biochim biophi
ra compon multipl signal cascad
 protein includ ra small gtpase act molecular switch gate
exchang guanosin triphosph gtp guanosin diphosph ra protein
activ bound gtp inact bound state protein cycl
two state activ ra first requir disloc inact
protein process catalyz guanin nucleotid exchang factor gef empti
nucleotid pocket occupi gtp activ ra concentration-depend process
facilit high intracellular level gtp ra possess intrins weak gtpase activ
hydrolyz gtp result deactiv ra accessori protein known
gtpase activ protein assist process enabl ra deactiv activ
stimul ligand mediat activ upstream rtk switch ra activ
state includ conform chang conduc interact downstream
signal protein refer ra effector effector frequent associ ra
signal raf part mapk pathway howev ra also involv signal
paradigm includ cascad
nucleotid exchang ra activ
ra preemin oncogen human ra famili homolog transform
tumorigen gene first identifi group virus caus sarcoma rat provid
etymolog class name rat sarcoma begin earli recogn
human cell contain sequenc homolog transform gene
human sequenc could similarli caus cancer result first identif oncogen
ra recogn first describ oncogen famili also common
genet driver human cancer ra famili mutat found tumor
sever common tumor high rate ra mutat includ lung adenocarcinoma
colorect adenocarcinoma pancreat ductal adenocarcinoma kra
commonli mutat ra oncogen repres ras-driven tumor
predomin mutat ra isoform tumor well papk der scienc
although lower frequenc mutat nra
hra also oncogen driver nra mutat commonli found ra
driver melanoma heme malign aml wherea hra mutat
associ urotheli cancer head neck cancer vasan et al clin cancer
activ mutat kra typic occur exon specif codon
colorect cancer harbor mutat one codon contrast
popul harbor mutat kra exon nra exon nccn similarli
kra mutat nsclc occur codon vast major codon
mutat codon interfer activ sever reduc gtp
hydrolysi therebi promot ra activ separ common mutat locu reduc
intrins gtp hydrolysi prevent coordin water molecul key reaction
commonli occur mutat nsclc kra repres
kra mutat diseas variant includ mutat
ferrer et al lung cancer similar way differ ra isoform
 may predomin driver tumor tumor also contain differ mix
mutat variant kra major variant found lung cancer minor
player pancreat biliari tract cancer kra domin
speci colorect cancer kra join preval
mechanist data suggest mutat variant differenti impact rel rate
gtp hydrolysi abil interact ra effector exampl suggest variabl
level ra activ therefor tumor virul hunter et al mol cancer
howev make prognost conclus mutat type complic
genet complex ra mutant tumor particularli lung cancer differ
base tumor histolog exampl kra mutat gener consid neg
prognost indic patient nsclc associ reduc surviv irrespect
treatment choic controversi remain regard conclus consid signific
heterogen clinic trial well suggest mutat variant exampl
may wors prognosi mutat certain set roman et al mol
cancer feb kra mutat lung cancer frequent exclus
driver mutat known respond pharmacolog intervent exampl
egfr ro howev tumor harbor kra mutat said genet
simpl frequent kra mutat tumor carri co-mut --
common exampl -- increas tumor aggress yet kra remain key
tumor commonli featur overexpress egfr believ
drive tumor growth escap intervent egfr base therapi includ
erbitux vectibix cornerston therapi although egfr express level
predict respons importantli kra mutat associ lack respons
therapi indic clinic need effect target kra signal
ra therapeut target given broad role ra mutat play oncogen
driver long consid ideal therapeut target howev despit
widespread recognit import famili decad studi littl progress
made field effect therapi ra mutat
ra present uniqu challeng drug develop hamper earli attempt inhibit
ra signal ra isoform high affin guanin nucleotid gtp
picomolar rang affin gtp ras-bind pocket high
intracellular concentr make ra nucleotid exchang effici importantli
characterist limit possibl ra inhibitor function compet gtp
bind pocket note approach use varieti kinas inhibitor howev
affin kinas adenosin triphosph atp substrat markedli lower micromolar
rang beyond challeng pose competit bind ras/gtp affin ra
protein lack attract hydrophob pocket could target even alloster modul
inhibitor properti produc long held view ra directli druggabl
target signific effort instead invest indirect inhibit strategi
farnesyl transferas inhibitor ra protein function membran bound signal transduc
associ ra membran depend seri post-transl
modif promin featur addit lipid chain ra process known
prenyl lipid prenyl occur c-termin protein semi-
conserv four residu membran target motif caax found sequenc
cystein repres aliphat residu termin residu prenyl lipid
conjug caax cystein residu follow aax residu proteolyt
cleav methyl group ad prenyl cystein minim membran repuls
due neg charg addit modif includ addit either palmit poly-
ra prenyl addit farnesyl isoprenoid enzym farnesyl transferas
given central enzym proper ra function becam major target
pharmacolog intervent signific bodi work demonstr farnesyl transferas
could inhibit ablat tumor growth varieti pre-clin model featur hra
mutat agent tipifarnib lonafarnib advanc far phase trial
varieti tumor howev effort ultim fail failur agent attribut
altern prenyl geranylgeranyl isoprenoid nra subject
hra altern pathway permit ra isoform associ membran
continu signal even farnesyl transferas inhibit papk der
prenyl requir ra membran bind signal
papk der scienc
direct target ra coval inhibitor attempt directli target ra saw
paradigm shift last decad adopt target perspect attempt
identifi chemic tractabl subset mutat ra protein start point drug
develop initi target work kra discuss previous mutat
codon common ra mutat cancer interf abil protein
catalyz gtp hydrolysi codon also adjac end guanin nucleotid pocket
gtp- phosphat locat gtp bound activ state patricelli et al cancer discov
variant major driver nsclc tumor base
preval importantli target mutat appear chemic achiev mutat
cystein residu suscept form coval bond potenc afford coval
bond key given high affin ra nucleotid pocket gtp
found wild type protein inhibitor specif variant would like improv
toler agent inhibit broader spectrum activ
broadli two strategi employ develop coval inhibitor shokat
colleagu use chemic tether techniqu start screen cystein reactiv
chemic fragment optim compound bind properti iter structur
chemistri process ostrem et al natur interestingli
molecul result process resid core nucleotid pocket
gtp/gdp bound extend coval attach previous
uncharacter pocket dub switch-ii pocket s-iip switch ii region
undergo signific conform chang kra cycl activ inact
state involv bind activ effector milburn et al scienc feb
inhibitor bind s-iip thought work varieti way
coval bond may interfer gtp bind compet gtp-
phosphat access pocket adjac codon class also thought stabil
resid maintain kra inact state prevent switch ii interact
jactiv effector patricelli et al
orient switch ii pocket cystein codon nucleotid pocket
altern approach describ kenneth westov group inhibitor occupi
guanin nucleotid pocket prevent bind gtp hunter et al proc natl
jun inhibitor also interact mutat cystein
codon form coval bond provid prolong inhibitor resid despit high affin
kra gtp thu prevent ra activ although work demonstr
gtp competit agent possibl industri program focus agent design
bind s-iip three advanc program undertaken janssen licens
wellspr biosciences/arax mirati
scientist primarili associ wellspr publish data character new lead
candid januari jane et al cell jan howev
drug appear enter clinic trial medacorp kol believ
program paus
mirati clinic trial underway lead candid candid
studi phase basket trial enrol patient kra
mutat receiv prior therapi deem unlik benefit
standard care trial includ escal phase dose expans
maximum toler dose three solid tumor cohort kra mutat dose
escal set begin patient lowest plan dose report
initi result trial investor anticip upcom present
american associ cancer research meet march focu
preclin data initi clinic data phase trial like
present
mirati evalu phase basket trial
featur dose escal expans arm well phase tumor specif treatment
cohort entri trial requir confirm kra mutat standard treatment
must unavail declin patient mirati plan dose escal
acceler titrat model illustr incorpor singl patient dose cohort
earli trial intra-pati dose escal rapidli accumul exposur data multipl
dose start dose trial qd compani plan escal
trial allow enrol expand certain dose escal still underway mirati
size trial support potenti singl arm approv base phase tumor expans
cohort slightli behind program initi data expect
possibl esmo
evalu program complic limit disclosur even pre-clin data
date specif formal data present focus develop strategi
character lead candid compound ultim advanc clinic
trial although believ disclos lead candid like reason
approxim clinic candid mirati addit present initi pre-clin data
similar view lead compound profil
contrast program worth note signific overlap chemistri strategi
structur current disclos compound program advanc
mirati well last disclos janssen/wellspr compound shown
target kra coval bond acrylamid warhead three program
connect acrylamid central quinazolinon piperazin group lastli three
program target s-iip pocket
amgen first substant present kra program occur
target ras-driven cancer meet decemb lead compound
piperazin quinazolinon seri potenc measur cell line includ kra
mutant mutant cell line serv neg control
phospho-erk measur mapk pathway inhibit hour
cell erk synonym mapk termin member one key
ras-medi signal cascad central regul cell prolifer inhibit
phosphoryl erk demonstr reduct kra signal drug concentr
requir achiev inhibit select paramet case erk phosphoryl
activ valu lower concentr prefer singl nm denot
potent inhibit drug similar result seen inhibit cell prolifer
respect serum half-lif mous model
minut bioavail dose steadi state volum distribut
vss l/kg
perform sever vitro experi compar lead last
describ janssen/wellspr compound compound potent inhibit coupl
nucleotid exchang gdp- gtp erk phosphoryl cell viabil cell
line describ nucleotid exchang key step kra activ remov
bound inact state permit gtp bind kra activ data suggest
inhibit prevent kra activ lock protein inact bound
state reduc mapk pathway activ erk phosphoryl result reduc
cell viabil differ potenc observ cell expect given lack
sensit cell specif agent
lead compound potent pre-clin assay
compound show dose depend increas plasma drug concentr
correl increas inhibit erk phosphoryl inhibit erk phosphoryl
maintain time even plasma concentr fell potenti suggest prolong
target occup lastli lead compound caus dose depend tumor regress mia
lead caus dose depend tumor regress xenograft model
mirati publish medicin chemistri work seri inhibitor well
identifi lead candid yet detail disclosur
surround clinic candid compani disclos initi data
contrast
half-lif hour iv dose mous pk model mirati
report bioavail oral dose importantli remain free
fraction adjust cell hour vss l/kg earli data
suggest program may display shorter half-lif reduc bioavail
similarli mirati report drug clearanc rate iv dose lower
clearanc amgn lead may result greater exposur
much els initi data report mirati compound
difficult make direct comparison due differ assay design howev note
patient enrol phase trial must abl eat standard
high-fat high-calor meal within minut suggest signific food effect drug
exposur bioavail indic similar
phospho erk incub kra
mutant cell phospho erk inhibit similar mutant cell line
activ seen cell wild type kra similarli show rang
activ inhibit varieti mutant cell line impact viabil cell
bear mutat wild type kra
respons xenograft model variabl mirror cell prolifer studi
model robust tumor regress seen wherea other moder diseas
control minor mutant xenograft saw tumor growth reason variabl
respons remain unclear howev genet heterogen model reflect
human tumor like play role
variabl activ xenograft model may influenc genet
open question tumor genet variabl influenc breadth depth
durabl clinic respons importantli major model test show least moder
activ earli work perform mirati other attempt defin resist
escap mechan may limit activ inhibitor aim field combo therapi
extend clinic respons work earli complic number parallel
signal feedback network ra play role well varieti passeng
mutat known associ kra mutat potenti therapi combin
inhibitor includ inhibitor mapk pathway agent target braf mek
inhibitor upstream receptor tyrosin kinas egfr inhibitor
regul cell cycl believ kra agent singl agent activ
anticip clinic use evolv combin regimen
synerg egfr inhibitor
earli data suggest select durabl activ mirati present initi pre-
clinic data clinic candid suggest highli select agent
potenti durabl respons pk work support daili oral dose
on-going phase trial began dose escal dose qd
highli select kra show select wild type kra
screen cystein contain peptid kra speci
significantli modifi data show impress select improv
toler contribut wide therapeut index
shown potenc cellular assay rang activ repres
improv view earlier gener inhibitor suggest activ
drug highli activ cell line patient deriv xenograft tumor model
regress observ test model importantli respons
model dose depend durabl higher dose produc complet regress
last long cessat dose although pre-clin profil far
complet initi characterist suggest drug could activ monotherapi larg
proport patient kra mutat
select durabl inhibit kra
sitravatinib immuno-oncolog program sitravatinib multi-kinas inhibitor
develop combin opdivo checkpoint refractori nsclc sitravatinib highli
potent inhibitor cellular famili kinas tyro mer sitravatinib also
potent inhibitor common oncolog driver kit pdgfr cellular
potenc rang sitravatinib also lower potenti clinic relev
activ ret trka kinas inhibitor
kit shown activ varieti tumor particularli activ area research
determin agent would combin well immunotherapi goal broaden
respons overcom resist mirati believ sitravatinib may ideal combin
partner immuno-oncolog agent target implic mainten
tumor microenviron treatment may therefor enhanc immun function
exampl inhibit target propos shift macrophag pro-inflammatori
phenotyp increas dendrit cell antigen present traffick effector
cell deplet immunosuppress popul treg myeloid deriv
suppressor cell aggreg chang expect shift tumor immun
microenviron immune-suppress immune-respons could implic
greater anti-tumor immun respons checkpoint blockad
lead indic sitravatinib treatment checkpoint refractori nsclc combin
bristol myer opdivo nivolumab inhibitor backbon therapi nsclc
recent shift treatment paradigm frontlin use increas patient without
address driver mutat patient expos agent earlier
treatment monotherapi use standard care frontlin therapi patient
high wherea patient low receiv platinum doublet frontlin
treatment howev prefer regimen patient low receiv
combin platinum doublet result shift popul
refractori patient grow move treatment paradigm analys
suggest patient checkpoint refractori
eu patient exhaust two treatment option singl line therapi need
find new treatment checkpoint refractori nsclc acut
phase trial sitravatinib opdivo nsclc phase singl
arm trial studi combin sitravatinib opdivo checkpoint refractori nsclc
enrol patient document progress checkpoint inhibitor
immedi prior line therapi interven therapi allow enrol patient
treat qd sitravatinib opdivo trial util signal find
design enrol expans gate clinic activ patient stratifi prior benefit
checkpoint inhibitor mean patient initi respond stabl diseas
progress would consid separ whose diseas primari
refractori checkpoint
primari endpoint trial orr secondari endpoint includ safety/toler
durat respons progression-fre surviv os pharmacokinet measur
trial design nsclc
initi data trial present iaslc world lung congress first
evalu patient confirm partial respons pr orr
saw tumor regress degre suggest combo broad activ
popul poor respons standard therapi mirati provid updat trial
april similarli posit first evalu patient therapi
pr translat orr unconfirm tumor regress
importantli clinic benefit show impress sign durabl updat
longest respond treatment durat greater week base preliminari activ
durabl rel benign toler profil featur mostli gr advers event
mani investor conclud program would good candid acceler
approv file base singl arm data
esmo mirati present updat data trial includ evalu patient
data cutoff combin still show broad activ patient
see degre tumor regress patient tumor regress
qualifi pr howev confirm translat confirm orr
unconfirm respond would elig subsequ confirm
patient came trial respons confirm progress
advers event withdraw consent remain respond
subsequ confirm yield orr phase trial
updat data esmo
concurr updat mirati share regulatori feedback end phase meet
meet mirati regul agre design control phase studi
effect preclud possibl pursu acceler approv base singl arm
data although design trial discuss contempl approv process
base orr standard acceler pathway need perform random trial
push back potenti approv timelin mind mani investor well increas
risk associ acceler pathway
phase trial sitravatinib opdivo nsclc base fda feedback mirati plan
phase trial sitravatinib opdivo vs docetaxel checkpoint refractori nsclc trial
enrol patient document tumor progress follow frontlin
checkpoint/chemotherapi keep standard practic patient known driver mutat
exclud patient random receiv either sitravatinib opdivo
trial employ innov design could support either acceler full approv
primari endpoint trial overal surviv os posit would support applic
full approv interestingli trial incorpor interim analysi orr compar
arm would support potenti acceler approv submiss secondari endpoint
includ durat respons safeti toler trial expect begin
interim orr analysi anticip primari os analysi
phase data give confid phase success investor respond neg
eros orr esmo realiz fda would requir random phase
trial approv view though still reason optim program
compar arm trial docetaxel agent compar sever trial
checkpoint inhibitor saw use push back treatment paradigm
advent expans immunotherapi lung cancer
importantli preliminari activ sitravatinib opdivo look highli favor compar
expect respons docetaxel even consid less impress updat esmo three
recent well power nsclc trial docetaxel-tr patient orr rang
durat respons rang orr trial current sit
preliminari estim dor although clinic experi less
sitravatinib opdivo regimen suggest reproduc risk note publish
histor perform docetaxel could overestim expect plan phase
trial given patient heavili pre-treat legaci docetaxel trial
preliminari sitravatinib opdivo activ compar favor histor docetaxel
sitravatinib expans opportun beyond checkpoint refractori nsclc mirati
advanc clinic program expand sitravatinib opdivo new indic treatment
set combo current studi phase trial checkpoint refractori bladder
cancer initi proof-of-concept data expect refractori bladder cancer
increasingli competit space also larg market opportun believ could drive
valu data compel mirati also studi neo-adjuv applic sitravatinib
opdivo kidney cancer rcc head neck cancer hnscc earli mechan
action data expect program
beigen collabor mirati licens sitravatinib beigen bgne china asia
exclud japan russia india australia new zealand beigen sponsor clinic
trial china australia studi sitravatinib combin tislelizumab beigen pd-
trial provid mirati clinic data sitravatinib second could
potenti enabl sitravatinib receiv label agnost
beigen studi combo checkpoint nave refractori nsclc rcc
proof-of-concept data expect sitravatinib tislelizumab also studi
checkpoint nave gastric ovarian cancer well checkpoint nave refractori
hepatocellular cancer proof-of-concept data indic could report
companyprogram/drugtherapeut areaeventtimingev typetri phaseamgen tumorsdata preclin oral trial dataphimirati sitravatinibnsclciniti phase trial opdivo cpi refractori sitravatinibrcc hnscciniti data combin opdivo pre-surg rcc trial dataphi/iimirati tumorsphas proof concept data kra trial dataphi/iimirati sitravatinibbladd cancerphas proof concept data cpi refractori bladder trial dataphiimirati sitravatinibnsclc rcc ovarianiniti phase data combin bgne tislelizumab nsclc rcc trial tumorsiniti data phase patient kra trial dataphimirati mocetinostatnsclcdata combin azn imfinzi checkpoint experienc trial dataphi/iiamgen tumorsiniti clinic data trial kra trial dataphimirati kra programtbaidentifi clinic candid target sitravatinibnsclcinterim data orr phase combo w/ opdivo cpi refractori nsclc vs trial dataphiiimirati sitravatinibnsclcprimari endpoint data os phase combo w/ opdivo cpi refractori nsclc vs trial dataphiiimirati mirati inc
mn except per share data
net incom tax
balanc sheet mn
chang
compani report svb leerink estim
